Endo Pharmaceuticals Articles
US FDA to allow generic copies of Endo's Opana
13 May 2013
Actavis confirms patent challenge to Endo's Fortesta
4 March 2013
Watson acquires Uteron Pharma; confirms Opana patent challenge
24 January 2013
Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion
21 December 2012
US patent settlements of Xopenex and Lidoderm
30 May 2012
Mersana inks ADC deal with Endo Pharma
8 March 2012
Endo Pharma in $180 million deal with BioDelivery Sciences
8 January 2012
Endo Pharma pulls out of axomadol deal with Grunenthal
19 August 2011
Endo Pharma sues Mylan over Frova patent infringement
17 August 2011
US FDA clears Mylan’s generic versions of Hyzaar and Cozaar and Watson’s copy of Lotrel; Watson settles with Endo
18 October 2010
Endo buys US generics firm Qualitest for $1.2 billion
29 September 2010
Endo Pharma to buy Penwest for around $144 million; submits NDA for new formulation of oxymorphone
10 August 2010
Endo Pharma to acquire HealthTronics in $233 million deal; plans to gain rights to SYNERGO system
7 May 2010
Curis and Bioniche each get $8 million milestones in respective deals with Debiopharm and Endo
15 February 2010
Endo names Alan Levin CFO
14 May 2009
Logical Therapeutics names Peter Lankau CEO
14 May 2009
Vernalis back from brink with 2008 results
5 May 2009
Endo completes Indevus acquisition
30 March 2009
Endo files response for Nebido application
23 March 2009
Endo set to return rights to painkiller skin patch
16 March 2009
Teikoku to help Eisai develop donepezil skin patch
16 March 2009
Endo licenses rights to Grunenthal's axomadol
16 March 2009
Opana growth drives Endo's profit up 15%
16 March 2009
Endo completes tender for Indevus
2 March 2009
Endo/Penwest settle Opana litigation
2 March 2009
Endo enters R&D deals with Harvard Univ and Aurigene
16 February 2009
Endo returns fentanyl inhaler to Alexza
9 February 2009
Lannett launches generic Symmetrel
22 December 2008
Illegal California pharmacy faces charges
2 June 2008
Vernalis FY 2007 income reaches $39.5M
5 May 2008
Vernalis/Endo Pharma withdraw Frova sNDA
14 April 2008
Endo names David Holveck as president and CEO
17 March 2008
FDA clears three new Opana ER strengths
10 March 2008
Vernalis announces staff cuts and restructuring
25 February 2008
CeNeS' price soars 70% on confirmation of takeover talks
11 February 2008
Strong Ph III data for ProStrakan/Endo's Rapinyl
24 December 2007
Orexo and Hospira sign Asia-Pacific Rapinyl deal
5 November 2007
Vernalis/Endo's Frova sNDA rejected by FDA
8 October 2007
FDA requests extension for Frova sNDA
20 August 2007
FDA accepts Vernalis' Frova filing
25 September 2006
Vernalis' losses for 1st-half 2006 down slightly
18 September 2006
EpiCept receives F&S Transdermal Drug Delivery award
28 August 2006
Endo submits Frova US sNDA for menstrual migraine
31 July 2006
Frova performs well in second Ph II MM study
15 May 2006
SkyePharma ends Propofol deal with Endo
1 May 2006
Endo to submit response to Appeal Court over oxycodone
1 August 2005
Good Ph II interim data on Vernalis' Frova
4 July 2005
Endo's 1st-qtr earnings drop 66%
22 April 2005
Positive data for Endo's Lidoderm patch in OA
11 April 2005
Endo president Peter Lankau also becomes CEO
14 March 2005
Vernalis: reduced losses for 2004
7 March 2005
Vernalis to co-promote Frova in N America
7 March 2005
Endo Pharma issues 2005 guidance
10 January 2005
Endo and Novartis will be key players in pain
20 December 2004
SkyePharma's DepoDur available in the USA
13 December 2004
Endo's shares jump on 3rd-qtr results
25 October 2004
Vernalis cuts first-half 2004 loss 50%
27 September 2004
Neuropathic pain mkt "to reach $4.83B by 2010"
13 September 2004
Endo gets rights to Orexo's Rapinyl
23 August 2004
Stock Commentary - Europe
2 August 2004
Vernalis leaps 104% on $400M Frova deal
26 July 2004
Stock Commentary - Europe
26 July 2004
Endo Pharma sees 2nd-qtr profits slump
26 July 2004
FDA OKs SkyePharma's DepoDur
24 May 2004
Endo net sales surge 49% in 2003
23 February 2004
EpiCept expects $100 million in milestones
19 January 2004
Endo creates four new group vice presidencies
5 January 2004
Endo Pharma converting to own sales reps
22 September 2003
Endo Pharma prices secondary offering
7 July 2003
Endo names Peter Llankau president, COO
21 April 2003
Endo's oxymorphone shows promise in back pain
31 March 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
Pre-merger Endo warrants exercisable
13 January 2003
SkyePharma licenses key drugs to Endo
13 January 2003
Endo files for oxymorphone approvals
6 January 2003
Endo sales to reach $440M in fiscal 2003
6 January 2003
Endo acquires BML Pharma
5 August 2002
Endo takes over speciality sales force from Ventiv
10 June 2002
Endo could face delays in filing NDA for MorphiDex
28 January 2002
Endo takes on Paxil 40mg in USA
19 November 2001
Endo Pharmaceuticals offering 11.4 mill shares
10 September 2001
Endos requested to conduct additional MorphiDex trial
28 September 2000
Endo Pharma, Algos merger finalized
17 August 2000
DuPont Generics Sold To Employee Group
2 July 1997
Showing 1-93 of 93 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
